Abstract
Classification of pediatric brain tumors with unusual histologic and clinical features may be a diagnostic challenge to the pathologist. We present a case of a 12-year-old girl with a primary intracranial tumor. The tumor classification was not certain initially, and the site of origin and clinical behavior were unusual. Genomic characterization of the tumor using a Clinical Laboratory Improvement Amendment (CLIA)-certified next-generation sequencing assay assisted in the diagnosis and translated into patient benefit, albeit transient. Our case argues that next generation sequencing may play a role in the pathological classification of pediatric brain cancers and guiding targeted therapy, supporting additional studies of genetically targeted therapeutics. © 2014 by the authors; licensee MDPI, Basel, Switzerland.
Author supplied keywords
Cite
CITATION STYLE
Glod, J., Song, M., Sharma, A., Tyagi, R., Rhodes, R. H., Weissmann, D. J., … Rodriguez-Rodriguez, L. (2014). Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer. Journal of Personalized Medicine, 4(3), 402–411. https://doi.org/10.3390/jpm4030402
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.